Virginie Chesnais,on behalf of the Groupe Francophone des Myélodysplasies,Aline Renneville,on behalf of the Groupe Francophone des Myélodysplasies,Andrea Toma,on behalf of the Groupe Francophone des Myélodysplasies,Jérôme Lambert,on behalf of the Groupe Francophone des Myélodysplasies,Marie Passet,on behalf of the Groupe Francophone des Myélodysplasies,Florent Dumont,on behalf of the Groupe Francophone des Myélodysplasies,Sylvie Chevret,on behalf of the Groupe Francophone des Myélodysplasies,Julie Lejeune,on behalf of the Groupe Francophone des Myélodysplasies,Anna Raimbault,on behalf of the Groupe Francophone des Myélodysplasies,Aspasia Stamatoullas,on behalf of the Groupe Francophone des Myélodysplasies,Christian Rose,on behalf of the Groupe Francophone des Myélodysplasies,Odile Beyne-Rauzy,on behalf of the Groupe Francophone des Myélodysplasies,Jacques Delaunay,on behalf of the Groupe Francophone des Myélodysplasies,Eric Solary,on behalf of the Groupe Francophone des Myélodysplasies,Pierre Fenaux,on behalf of the Groupe Francophone des Myélodysplasies,François Dreyfus,on behalf of the Groupe Francophone des Myélodysplasies,Claude Preudhomme,on behalf of the Groupe Francophone des Myélodysplasies,Olivier Kosmider,on behalf of the Groupe Francophone des Myélodysplasies,Michaela Fontenay,on behalf of the Groupe Francophone des Myélodysplasies

View Articletitled, Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion

Supplemental data

KIT D816V–mutated bone marrow mesenchymal stem cells in indolent systemic mastocytosis are associated with disease progression

Andres C. Garcia-Montero,Maria Jara-Acevedo,Ivan Alvarez-Twose,Cristina Teodosio,Laura Sanchez-Muñoz,Carmen Muñiz,Javier I. Muñoz-Gonzalez,Andrea Mayado,Almudena Matito,Carolina Caldas,Jose M. Morgado,Luis Escribano,Alberto Orfao

View Articletitled, KIT D816V–mutated bone marrow mesenchymal stem cells in indolent systemic mastocytosis are associated with disease progression

THROMBOSIS AND HEMOSTASIS

Prostaglandin E synthase is upregulated by Gas6 during cancer-induced venous thrombosis

Meghedi N. Aghourian,Catherine A. Lemarié,Francois-René Bertin,Mark D. Blostein

View Articletitled, Prostaglandin E synthase is upregulated by Gas6 during cancer-induced venous thrombosis

Supplemental data

Macrophage receptor SR-AI is crucial to maintain normal plasma levels of coagulation factor X

Vincent Muczynski,Amine Bazaa,Cécile Loubière,Amélie Harel,Ghislaine Cherel,Cécile V. Denis,Peter J. Lenting,Olivier D. Christophe

View Articletitled, Macrophage receptor SR-AI is crucial to maintain normal plasma levels of coagulation factor X

Supplemental data

BLOOD WORK

Familial hypertriglyceridemia manifests with pancytopenia and bone marrow pseudo–Niemann-Pick cells

Jose D. Sandoval-Sus,Ling Zhang

View Articletitled, Familial hypertriglyceridemia manifests with pancytopenia and bone marrow pseudo–Niemann-Pick cells

Signet ring plasma cell myeloma

Jonathan H. Gralewski,Soumya Pandey

View Articletitled, Signet ring plasma cell myeloma

Cover Image

Cover Image

CD115⁺-derived macrophages from wild-type C57BL/6 mice were incubated with human coagulation factor X (FX). Cells were then immunostained for human FX (green), while nuclei and polymerized actin were counterstained using 4′,6-diamidino-2-phenylindole (blue) and Alexa 647–labeled phalloidin (magenta), respectively. Images were acquired using widefield microscopy, original magnification ×63. See the article by Muczynski et al on page 778.
Front Matter
Table of Contents
Back Matter
Editorial Board

All Issues

Advertisement intended for health care professionals

Email alerts

First Edition Alert

Latest Issue Alert

Latest
Most Read
Most Cited

For how long has this problem been there?

Targeting CD47: many misses; hopeful for a hit

Woyach JA, Burbano GP, Ruppert AS, et al. Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL. Blood. 2024;143(16):1616-1627.

MRD-guided zanubrutinib, venetoclax and obinutuzumab in relapsed CLL: primary endpoint analysis from the CLL2-BZAG trial

Sickle Cell Trait Does Not Cause "Sickle Cell Crisis" Leading to Exertion-Related Death: A Systematic Review

Advertisement intended for health care professionals

Table of Contents

BLOOD FLASHBACK

Dameshek W. Some speculations on the myeloproliferative syndromes [editorial]. Blood. 1951;6(4):372-375.

INSIDE BLOOD COMMENTARIES

Platelet antibody identification: toward a solution

BCR-ABL1 mutation ≠ ponatinib resistance
Clinical Trials & Observations

B cells help CD8⁺ T-cell responses

FOXO discriminates tonic from chronic in DLBCL

Origin of stem cells in the BM niche: new clues from mastocytosis

Gas6 fueling tumor-mediated thrombosis

PLENARY PAPER

CRISPR/Cas9-mediated conversion of human platelet alloantigen allotypes

REVIEW ARTICLE

Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma
Clinical Trials & Observations

HOW I TREAT

How I treat recurrent deep-vein thrombosis

CLINICAL TRIALS AND OBSERVATIONS

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients
Clinical Trials & Observations

Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment
Clinical Trials & Observations

IMMUNOBIOLOGY

Induction of WT1-specific human CD8⁺ T cells from human HSCs in HLA class I Tg NOD/SCID/IL2rgKO mice

CD20⁺ B-cell depletion therapy suppresses murine CD8⁺ T-cell–mediated immune thrombocytopenia
Brief Report

LYMPHOID NEOPLASIA

FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas

MYELOID NEOPLASIA

Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion

KIT D816V–mutated bone marrow mesenchymal stem cells in indolent systemic mastocytosis are associated with disease progression

THROMBOSIS AND HEMOSTASIS

Prostaglandin E synthase is upregulated by Gas6 during cancer-induced venous thrombosis

Macrophage receptor SR-AI is crucial to maintain normal plasma levels of coagulation factor X

BLOOD WORK

Familial hypertriglyceridemia manifests with pancytopenia and bone marrow pseudo–Niemann-Pick cells

Signet ring plasma cell myeloma

Email alerts

ASH Publications

American Society of Hematology

Issue Archive

Table of Contents

BLOOD FLASHBACK

INSIDE BLOOD COMMENTARIES

BCR-ABL1 mutation ≠ ponatinib resistance Clinical Trials & Observations

PLENARY PAPER

REVIEW ARTICLE

Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma Clinical Trials & Observations

HOW I TREAT

CLINICAL TRIALS AND OBSERVATIONS

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients Clinical Trials & Observations

Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment Clinical Trials & Observations

IMMUNOBIOLOGY

CD20+ B-cell depletion therapy suppresses murine CD8+ T-cell–mediated immune thrombocytopenia Brief Report

LYMPHOID NEOPLASIA

MYELOID NEOPLASIA

THROMBOSIS AND HEMOSTASIS

BLOOD WORK

Cover Image

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only

BCR-ABL1 mutation ≠ ponatinib resistance
Clinical Trials & Observations

Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma
Clinical Trials & Observations

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients
Clinical Trials & Observations

Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment
Clinical Trials & Observations

CD20⁺ B-cell depletion therapy suppresses murine CD8⁺ T-cell–mediated immune thrombocytopenia
Brief Report